Clinical trials
PSMA Positive Tumors or Tumor Tissues clinical trials
Below are recruiting psma positive tumors or tumor tissues clinical trials, each written for real people, not researchers. We’re tracking 1,296 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04855656RecruitingPhase 1
Lunresertib for advanced solid tumors with specific gene changes
This early-phase trial tests lunresertib alone or with other study drugs in people with advanced solid tumors that have certain tumor gene changes. It aims to see whether the treatment is safe and whether it can help shrink or control cancer.
Los Angeles, CaliforniaAges 12 years+ - NCT04921917Recruiting
Exercise during treatment for soft tissue sarcoma in an arm or leg
This trial studies whether adding an exercise program helps people with soft tissue sarcoma in an arm or leg during a planned treatment course. The treatment they look at is radiation before surgery, then surgery to remove the tumor, and they want to see how exercise affects outcomes and recovery.
Durham, North CarolinaAges 18–85 - NCT04794686Recruiting
Study for children with a brain tumor with multilayer rosettes
This registry research program collects information and tumor samples from people with a specific type of brain embryonal tumor (with multilayer rosettes). It may help researchers understand the tumor better and improve future treatments.
Hackensack, New JerseyAges Any age - NCT04852328RecruitingPhase 2
Testing CUE-101 schedules before treatment for HPV16 throat cancer
This Phase 2 trial studies different timing “schedules” of CUE-101 given before surgery or before chemoradiation for HPV16-positive oropharyngeal throat cancer. The goal is to see if CUE-101 can help the body respond better and potentially improve outcomes.
St Louis, MissouriAges 18 years+ - NCT04794972RecruitingPhase 1
Testing a targeted antibody for advanced solid tumors
This Phase 1 trial tests a new antibody drug (GNC-039) that targets a specific feature found on some cancer cells. It is for adults with solid tumors that have come back or stopped responding to standard treatment, aiming to see safety and early signs of effectiveness.
Beijing, Beijing MunicipalityAges 18 years+ - NCT04683250RecruitingPhase 1/Phase 2
RET-targeting drug study for advanced cancers with RET changes
This trial tests an “RET-inhibitor” medicine (TAS0953/HM06) for advanced solid tumors that have RET gene changes. It may help shrink tumors by blocking cancer growth signals from the RET gene.
Orange, CaliforniaAges 18 years+ - NCT04605770RecruitingPhase 2
Pemetrexed and cisplatin for advanced soft tissue cancer
This Phase 2 trial tests whether pemetrexed plus cisplatin can shrink advanced or metastatic soft tissue sarcoma. It may help people whose cancer has spread and who can safely receive chemotherapy.
SeoulAges 19 years+ - NCT04534127Recruiting
DaRT radiation device for skin and mouth or superficial tumors
This trial tests a targeted radiation device (DaRT seeds) to treat certain cancers on the skin, in the mouth, or in superficial soft tissue. It may help when standard treatment (like surgery or regular radiation/chemo) hasn’t worked, isn’t safe, or isn’t wanted.
JerusalemAges 18 years+ - NCT04469530RecruitingPhase 2
Sirolimus plus low-dose chemotherapy for high-risk childhood tumors
This Phase 2 study tests whether sirolimus combined with low-dose (“metronomic”) chemotherapy can help children and young adults with certain high-risk solid tumors stay in remission or reduce recurrence risk. It is designed for people whose cancer has responded well to initial treatment, with only minimal or no visible disease on scans.
Atlanta, GeorgiaAges 1–30 - NCT04421846Recruiting
Studying the causes of severe seizures and immune brain swelling
This study looks at what causes severe seizure episodes (“status epilepticus”) and a related immune condition that affects the brain (“dysimmune encephalitis”). The goal is to better understand the disease process, which may guide future care.
ParisAges 2 years+ - NCT04300556RecruitingPhase 1/Phase 2
Testing an antibody-drug for advanced certain cancers
This early-phase trial tests a treatment called MORAb-202, an antibody “delivery” drug, to see if it’s safe and can help shrink or control certain advanced cancers. It may help people whose tumors match the study’s specific cancer types and prior treatment history.
Tucson, ArizonaAges 18 years+ - NCT04307277RecruitingPhase 3
Chemotherapy before and after surgery for high-risk soft tissue sarcoma
This trial tests whether giving chemotherapy both before and after surgery helps people with high-risk soft tissue sarcoma live longer and prevents the cancer from coming back. It aims to see if this treatment plan is more effective than surgery alone.
BesançonAges 18 years+ - NCT04219202Recruiting
Pre-surgery radiation for retroperitoneal soft tissue cancer
This study tests giving special radiation (ions) before surgery for a specific cancer in the back of the abdomen (retroperitoneal soft tissue sarcoma). The goal is to shrink or control the tumor so surgery may be safer or more effective.
HeidelbergAges 18 years+ - NCT04219254RecruitingPhase 1/Phase 2
Testing BI-1206 with pembrolizumab for advanced solid cancers
This early-phase trial studies BI-1206 together with pembrolizumab to treat advanced solid tumors. It may be an option if your cancer has progressed after prior anti–PD-1/PD-L1 treatment (or, in some groups, if standard treatments aren’t suitable).
Los Angeles, CaliforniaAges 18 years+ - NCT04104776RecruitingPhase 1/Phase 2
Test drug tulmimetostat for advanced cancers and lymphomas
This early-phase study tests tulmimetostat (DZR123) to shrink or control advanced solid tumors and certain lymphomas, and it may also test a combination in some prostate cancer groups. If you qualify, you’ll receive the study drug and be monitored closely, including blood tests and a request for tumor tissue to look for biomarkers.
Tampa, FloridaAges 18 years+ - NCT04040205RecruitingPhase 2
Abemaciclib for sarcoma with specific cell-growth gene changes
This trial tests abemaciclib (a cancer medicine) in adults with advanced, unresectable bone or soft-tissue sarcoma that has certain gene changes in the “CDK pathway.” It aims to shrink tumors or slow growth in people whose tumors match the study’s biomarker and lab requirements.
Jacksonville, FloridaAges 18 years+ - NCT04099290Recruiting
Blood DNA test in newly diagnosed head and neck cancer
This study looks at “circulating tumor DNA” (tumor DNA found in blood) in people with newly diagnosed, locally advanced head and neck squamous cell cancer. Researchers want to see how the blood DNA levels relate to the cancer and how it may guide treatment after surgery.
Chapel Hill, North CarolinaAges 18 years+ - NCT03934372RecruitingPhase 1/Phase 2
Ponatinib for children with relapsed or hard-to-treat cancers
This trial tests a targeted therapy called ponatinib in children whose leukemia, lymphoma, or solid tumor has come back or hasn't improved with standard treatments. The drug works by blocking signals that help cancer cells grow, and the study looks at how safe and effective it is for different cancer types.
GhentAges 1–17 - NCT03988283RecruitingPhase 1
Personalized DNA vaccine for recurrent childhood brain tumors
This trial tests a personalized DNA vaccine made from your tumor’s DNA (neoantigens) to help your immune system fight the cancer. It is designed for children and young adults with certain recurrent or newly diagnosed brain/spine tumors, after they have had other standard treatments and tumor tissue is available for testing.
St Louis, MissouriAges Up to 25 years - NCT03810339RecruitingPhase 2
Check a POLE/POLD cancer drug for non–MSI-high tumors
This Phase 2 trial studies toripalimab (JS001), given alone, in people whose tumors have specific POLE or POLD gene mutations but do not have MSI-H/dMMR. If it works, it may help shrink or control advanced solid tumors that have not responded to standard treatment.
Guangzhou, GuangdongAges 18–75 - NCT03526835RecruitingPhase 1/Phase 2
Study of MCLA-158 for advanced solid tumors
This trial tests a new experimental drug called MCLA-158 (petosemtamab) for people with advanced solid tumors, especially head and neck cancer or colorectal cancer, that have not responded to standard treatments. The study aims to see if this drug can shrink tumors or slow their growth.
La Jolla, CaliforniaAges 18 years+ - NCT03300830Recruiting
Testing tumors linked to viruses, HIV, and immune disorders
This study collects and analyzes tumor tissue to learn what drives certain cancers and growths linked to viruses, HIV, and immune system problems. Results may help researchers understand disease causes and point to better future treatments.
Bethesda, MarylandAges 18 years+ - NCT03454035RecruitingPhase 1
Combination of two study drugs for advanced pancreatic and other solid tumors
This trial tests two drugs, ulixertinib and palbociclib, taken together to see if they can shrink tumors in patients with advanced pancreatic cancer, melanoma, or other solid tumors. It may be an option for people who have already tried standard treatments.
Chapel Hill, North CarolinaAges 18–99 - NCT03465592RecruitingPhase 1/Phase 2
Nivolumab after mismatched bone marrow transplant for sarcoma
This trial studies nivolumab (an immune treatment) in people with sarcoma who already had a partially mismatched bone marrow transplant. It may help the new immune system recognize and attack cancer, and researchers will also watch closely for side effects like GVHD (immune reaction after transplant) and autoimmune problems.
St. Petersburg, FloridaAges 1–40
Hear when a new PSMA Positive Tumors or Tumor Tissues trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for psma positive tumors or tumor tissues?
- Yes. Clin2 currently lists 1,296 recruiting psma positive tumors or tumor tissues studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a psma positive tumors or tumor tissues trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a psma positive tumors or tumor tissues trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.